Abstract
A double-blind, randomized, phase 2b screening trial (SOLTI-0701) of sorafenib, an oral multikinase inhibitor, in patients with HER2-negative advanced breast cancer (BC), showed a statistically significant improvement in progression-free survival (PFS) in the sorafenib + capecitabine arm versus the placebo + capecitabine arm: 6.4 versus 4.1 months (hazard ratio = 0.58; one-sided P = 0.0006). Grade 3/4 toxicities were comparable except G3 hand-foot skin reaction/syndrome (HFSR/HFS) (44% vs. 14%). These results support a phase 3 trial of sorafenib + capecitabine in advanced BC.
Highlights
IntroductionData were statistically processed by nonparametric Mann–Whitney U test, Spearman correlation coefficient and Pearson chi-square
A double-blind, randomized, phase 2b screening trial (SOLTI-0701) of sorafenib, an oral multikinase inhibitor, in patients with HER2-negative advanced breast cancer (BC), showed a statistically significant improvement in progression-free survival (PFS) in the sorafenib + capecitabine arm versus the placebo + capecitabine arm: 6.4 versus 4.1 months
We have shown that nestin expression is higher in breast carcinoma with a basal phenotype [1] and collagen triple helix repeat containing 1 (CTHRC1) and periostin may predict bone metastasis of breast cancer [2]
Summary
Data were statistically processed by nonparametric Mann–Whitney U test, Spearman correlation coefficient and Pearson chi-square Results Both CTHRC1 stromal (P = 0.013) and nestin epithelial expression (P = 0.001) were higher in the triple-negative subtype. Nestin expression was associated with vimentin expression in breast cancer cells (r = 0.491; P
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have